Novavax (NASDAQ: NVAX) on Monday announced an agreement with the US government under which Maryland-based biotech will initially provide
3.2M doses of its COVID-19 vaccine subject to FDA approval and CDC clearance.
The agreement with the US Department of Health and Human Services (HHS), in collaboration with the Department of Defense, will include the first protein-based
COVID-19 shot for the country's immunization campaign. Chief Executive Stanley C.
Eric noted, "We are approaching physicians, healthcare organizations, and consumers who are waiting for a protein-based vaccine option, possibly one step closer to offering their own vaccine.
" Glad to come. " Last month, a federal agency's advisory committee voted to recommend emergency clearance for the NVX-CoV2373 vaccine to prevent.
COVID-19 in people 18 years of age or older.